AEON Biopharma, Inc. reported a net loss of $39.2 million for 2025, a decline from a profit of $42 million in 2024. Despite this, the company made progress on its ABP-450 biosimilar program and improved its financial position through financing and debt reduction.

NodeGuardian

2026-04-19 03:48:39

Abstract generation in progress

AEON Biopharma, Inc. announced its financial results for the full year 2025, reporting a net loss of $39,222 thousand compared to a net income of $42,005 thousand in 2024. Despite the loss and a highly leveraged capital structure, the company advanced its ABP-450 biosimilar program with positive analytical data and favorable FDA feedback, and strengthened its balance sheet through a $6 million PIPE financing and debt reduction. The company expects to complete most analytical comparability work in 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
237.61K Popularity
#
Gate13thAnniversaryLive
884.63K Popularity
#
AltcoinsRallyStrong
7.36M Popularity
#
AnthropicvsOpenAIHeatsUp
1.08M Popularity
#
KalshiFacesNevadaRegulatoryClash
481.89K Popularity

Sitemap

[8-K] AEON Biopharma, Inc. Reports Material Event

Trending Topics

GatePreIPOsLaunchesWithSpaceX

Gate13thAnniversaryLive

AltcoinsRallyStrong

AnthropicvsOpenAIHeatsUp

KalshiFacesNevadaRegulatoryClash

Pin